Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection

Chun-Hao Huang; Ko-Chuan Lee; Jennifer A Doudna

doi:10.1016/j.trecan.2018.05.006

Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection

Trends Cancer. 2018 Jul;4(7):499-512. doi: 10.1016/j.trecan.2018.05.006. Epub 2018 Jun 13.

Authors

Chun-Hao Huang¹, Ko-Chuan Lee¹, Jennifer A Doudna²

Affiliations

¹ Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.
² Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA; Department of Chemistry, University of California, Berkeley, CA 94720, USA; Howard Hughes Medical Institute, University of California, Berkeley, CA 94720, USA; MBIB Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; Innovative Genomics Institute, University of California, Berkeley, CA 94720, USA. Electronic address: doudna@berkeley.edu.

Abstract

Cancer is a complex disease caused by combinations of cellular genetic alterations and heterogeneous microenvironments. The use of the robust and programmable CRISPR-Cas systems has greatly improved genome editing for precision cancer modeling and enabled multiplexed genetic manipulation for cancer treatment and mutation detection. In this review, we outline the current CRISPR-Cas toolkit, and discuss the promises and hurdles in translating this revolutionary technology into effective and safe clinical applications for cancer treatment and diagnosis.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
CRISPR-Cas Systems*
Gene Editing
Humans
Neoplasms* / diagnosis
Neoplasms* / genetics
Neoplasms* / therapy

Grants and funding

HHMI_/Howard Hughes Medical Institute/United States